A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of one dose of imeglimin versus placebo after 18 weeks of treatment in subjects with type 2 diabetes mellitus
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2015
At a glance
- Drugs Imeglimin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Poxel
- 23 Nov 2015 Results were presented at the World Congress on Insulin Resistance and Cardiovascular Diseases 2015, according to a Poxel media release.
- 07 Oct 2015 Additional data will be presented at the World Congress on Insulin Resistance and Cardiovascular Diseases in November, as per Poxel media release.
- 04 Jun 2015 Results published in the Poxel Media Release.